LPA受容体
シグナル伝達経路
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1315 | Ki16425 | <1 mg/mL | 94 mg/mL | 94 mg/mL |
| S2906 | Ki16198 | <1 mg/mL | 96 mg/mL | 35 mg/mL |
| S8345 | ONO-7300243 | <1 mg/mL | 92 mg/mL | 46 mg/mL |
- LPA Receptor阻害剤(3)
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1315 |
Ki16425Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6. |
Ethanol intake and preference in male mice treated with Ki16425 during 24 h. Ethanol intake (A) and ethanol preference (B) in wild-type mice treated with vehicle or Ki16425 (5 and 20 mg/kg, i.p.).
|
|
| S2906 |
Ki16198Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6. |
Pain behavior and EDG2 and Nav1.8 expression after intrathecal injection of LPA. A LPA decreased PWTs (n = 8), and this was attenuated by the EDG2 antagonist Ki16198. B, C LPA up regulated EDG2 expression in L4-6 DRGs (n = 6). D, E Nav1.8 expression on L4-6 DRGs increased after LPA injection (n = 6). *P<0.05, **P<0.01, ***P<0.001.
|
|
| S8345 |
ONO-7300243ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM. |
